Journal Mobile Options
Table of Contents
Vol. 23, No. 3, 2002
Issue release date: May–June 2002 (September 2002)
Section title: Research Article
Tumor Biol 2002;23:123–129
(DOI:10.1159/000064028)

Production of Macrophage Migration Inhibitory Factor by Human and Murine Neuroblastoma

Bin Q. · Johnson B.D. · Schauer D.W. · Casper J.T. · Orentas R.J.
Department of Pediatrics, Section of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisc., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: 12/14/2001
Accepted: 5/14/2002
Published online: 9/5/2002

Number of Print Pages: 7
Number of Figures: 4
Number of Tables: 0

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI

Abstract

Tumor cells avoid immune recognition by subverting the ability of the immune system to mount an inflammatory response that generates cytotoxic effector cells. This can be achieved through cytokine production by the tumor itself. Our objective was to determine the cytokine profile of neuroblastoma (NB) lesions in tumor vaccine models. We found that the murine NB cell line, Neuro2a, secretes macrophage migration inhibitory factor, MIF, a multifunctional cytokine with the potential to block effective immune responses to a tumor. Patient-derived NB cell lines were also found to produce MIF. MIF production by NB was documented at the level of RNA by RNAse protection, soluble cytokine production by ELISA, and in a macrophage migration assay. Our studies also confirmed reports of IL-6 production by human NB cell lines. NB culture-derived MIF was also shown to activate tumor cell migration. This supports the hypothesis that MIF is a tumor-derived cytokine that may play a role in NB aggressiveness and evasion of immune recognition.


Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: 12/14/2001
Accepted: 5/14/2002
Published online: 9/5/2002

Number of Print Pages: 7
Number of Figures: 4
Number of Tables: 0

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Isaacs H Jr: Neuroblastoma. Tumors of the Fetus and Newborn. Philadelphia, Saunders, 1997.
  2. Brodeur GM, Castleberry RP: Neuroblastoma; in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology. Philadelphia, Lippincott-Raven, 1997.
  3. Katoka Y, Matsumura T, Yamamoto S, Sugimoto S, Sawada T: Distinct cytotoxicity against neuroblastoma cells of peripheral blood and tumor-infiltrating lymphocytes from patients with neuroblastoma. Cancer Lett 1993;73:11–21.
  4. Fowler CL, Brooks SP, Rossman JE, Cooney DR: Combined preoperative and postoperative immunotherapy for C1300 neuroblastoma. J Pediatr Surg 1993;28:420–427.
  5. Kuge S, Watanabe K, Makino K, Tokuda Y, Mitomi T, Kawamura N, Habu S, Nishimura T: Interleukin-12 augments the generation of autologous tumor-reactive CD8+ cytotoxic T lymphocytes from tumor-infiltrating lymphocytes: Jpn J Cancer Res 1995;86:135–139.
  6. Foreman NK, Rill DR, Coustan-Smith E, Douglass EC, Brenner MK: Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer 1993;67:933–938.
  7. Katsanis E, Orchard PJ, Bausero MA, Gorden KB, McIvor RS, Blazar BR: Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunother 1997;15:81–90.
  8. Truitt RL, Piaskowski V, Kirchner P, McOlash L, Camitta BM, Casper JT: Immunologic evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial. J Immunother 1992;11:274–285.

    External Resources

  9. Ziegler MM, Ishizu H, Nagabuchi E, Takada N, Arya G: A comparative review of the immunobiology of murine neuroblastoma and human neuroblastoma. Cancer 1997;79:1757–1766.
  10. Knezevic-Cuca J, Stansberry KB, Johnston G, Zhang J, Keller ET, Vinik AI, Pittenger GL: Neurotrophic role of interleukin-6 and soluble interleukin-6 receptors in N1E-115 neuroblastoma cells. J Neuroimmunol 2000;102:8–16.

    External Resources

  11. Goswami S, Gupta A, Sharma SK: Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J Neurochem 1998;71:1837–1845.

    External Resources

  12. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993;365:756–759.
  13. Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K, Bucala R: Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med 1995;7:781–788.
  14. Kleeman R, Rorsman H, Rosengren E, Mischke R, Mai NT, Bernhagen J: Dissection of the enzymatic and immunologic functions of macrophage migration inhibitory factor. Eur J Biochem 2000;267:7183–7192.

    External Resources

  15. Calandra T, Bernhagen J, Mitchell RA, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994;179:1895–1902.
  16. Jüttner S, Bernhagen J, Metz CN, Röllinghoff M, Bucala R, Gessnser A: Migration inhibitory factor induces killing of Leishmania major by macrophages: Dependence on reactive nitrogen intermediates and endogenous TNF-α. J Immunol 1998;161:2383–2390.

    External Resources

  17. Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R: An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 1999;5:181–191.
  18. Ogawa H, Nishihara J, Sato Y, Kondo M, Takahashi N, Oshima T, Todo S: An antibody for macrophage migration inhibitory factor suppresses tumor growth and inhibits tumor-associated angiogenesis. Cytokine 2000;12:309–314.
  19. Abe R, Peng T, Sailors J, Bucala R, Metz CN: Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol 2001;166:747–753.

    External Resources

  20. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld R: Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991;51:144–149.

    External Resources

  21. Gordon MR, Chida K, Takata I, Myrvik QN: Macrophage migration inhibition induced by MDP, LPS, PMA, and MIF/MAF: Reversal by macrophage migration enhancement factor (MEF), L-fucose, L-fucosyl BSA, D-mannose, and D-mannosyl BSA. J Leukoc Biol 1987;42:197–203.

    External Resources

  22. Bernhagen J, Bacher M, Calandra T, Metz CN, Doty SB, Donnelly T, Bucala R: An essential role for macrophage migration inhibitory factor in tuberculin delayed-type hypersensitivity reaction. J Exp Med 1996;183:277–282.
  23. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68–71.
  24. Calandra T, Spiegel LA, Metz CN, Bucala R: Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci USA 1998;95:11383–11388.
  25. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihara J: Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 2000;275:444–450.
  26. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J: High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 1999;264:751–758.

    External Resources

  27. Kleeman R, Hausser A, Geiger G, Mischke, R, Burger-Kentischer A, Flieger O, Johannes F-J, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, Bernhagen J: Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000;408:211–216.
  28. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999;190:1375–1382.
  29. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY: Role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 1998;160:5693–5696.
  30. Kitaichi N, Ogasawara K, Iwabuchi K, Nishihira J, Namba K, Onoe K, Konishi J, Kotake J, Matsuda H, Onoe K: Different influence of macrophage migration inhibitory factor (MIF) in signal transduction pathway of various T cell subsets. Immunobiology 2000;201:356–367.

    External Resources

  31. Ferrer FA, Pantschenko AG, Miller LJ, Anderson K, Grunnet M, McKenna PH, Kreutzer D: Angiogenesis and neuroblastomas: Interleukin-8 and interleukin-8 receptor expression in human neuroblastoma. J Urol 2000;164:1016–1020.
  32. Satoh J, Kurohara K, Yukitake M, Kuroda Y: Interleukin-15, a T-cell growth factor, is expressed in human neural cell lines and tissues. J Neurol Sci 1998;155:170–177.

    External Resources

  33. Condorelli F, Sortino MA, Stella AM, Canonico PL: Relative contribution of different receptor subtypes in the response of neuroblastoma cells to tumor necrosis factor-alpha. J Neurochem 2000;75:1172–1179.
  34. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R: Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 1994;33:14144–14155.

    External Resources

  35. Pastrana DV, Raghavan N, Fitzgerald P, Eisinger SW, Metz C, Bucala R, Schleimer RP, Bickel C, Scott AL: Filarial nematode parasites secrete a homologue of the human cytokine macrophage migration inhibitory factor. Infect Immun 1998;66:5955–5963.

    External Resources

  36. Kovalchuk LV, Khoroshilova-Maslova IP, Gankovskaya LV, Krainova TA, Gunorova RA, Ilatovskaya LV, Marteushev AV, Tumanov AV: Natural complex of cytokines is a potent stimulant to posttraumatic regeneration in rabbit cornea. J Ocul Pharmacol Ther 1996;12:271–279.
  37. Abe R, Shimizu AR, Ohkawara A, Nishihira J: Enhancement of macrophage migration inhibitory factor (MIF) expression in injured epidermis and cultured fibroblasts. Biochim Biophys Acta 2000;1500:1–9.
  38. Hermanowski-Vosatka A, Mundt SS, Ayala JM, Goyal S, Hanlon WA, Czerwinski RM, Wright SD, Whitman CP: Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry 1999;38:12841–12849.

    External Resources

  39. Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Okuta H, Ogata A, Shindoh M, Ohbuchi T, Kawakami Y: Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 2000;89:334–341.
  40. Bernhagen J, Calandra T, Bucala R: Regulation of the immune response by macrophage migration inhibitory factor: Biological and structural features. J Mol Med 1998;76:151–161.

    External Resources

  41. Mitchell RA, Bucala R: Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol 2000;10:359–366.

    External Resources